Holocene Advisors LP Cuts Holdings in Alkermes plc $ALKS

Holocene Advisors LP lowered its stake in Alkermes plc (NASDAQ:ALKS) by 13.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,469,030 shares of the company’s stock after selling 384,738 shares during the period. Holocene Advisors LP owned about 1.50% of Alkermes worth $74,071,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in ALKS. Royal Bank of Canada increased its stake in shares of Alkermes by 117.2% during the first quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock worth $9,098,000 after buying an additional 148,696 shares during the period. Ashton Thomas Private Wealth LLC purchased a new position in Alkermes in the first quarter worth approximately $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Alkermes by 4.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock worth $15,927,000 after acquiring an additional 20,091 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Alkermes by 1.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock worth $1,249,000 after acquiring an additional 551 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Alkermes by 2.8% in the 2nd quarter. Bank of Montreal Can now owns 28,856 shares of the company’s stock valued at $826,000 after purchasing an additional 799 shares during the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insider Transactions at Alkermes

In other news, EVP David Joseph Gaffin sold 2,034 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $29.29, for a total transaction of $59,575.86. Following the transaction, the executive vice president directly owned 237,660 shares in the company, valued at approximately $6,961,061.40. This trade represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $29.72, for a total transaction of $267,480.00. Following the completion of the transaction, the executive vice president directly owned 89,389 shares in the company, valued at $2,656,641.08. The trade was a 9.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 157,434 shares of company stock worth $5,305,794 in the last three months. Corporate insiders own 4.40% of the company’s stock.

Alkermes Stock Performance

Shares of ALKS stock opened at $28.00 on Tuesday. The stock’s 50-day moving average is $31.58 and its two-hundred day moving average is $30.19. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.32. The firm has a market cap of $4.67 billion, a price-to-earnings ratio of 19.58, a PEG ratio of 6.92 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.14). The firm had revenue of $384.55 million during the quarter, compared to analysts’ expectations of $380.44 million. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The firm’s revenue for the quarter was down 10.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.05 earnings per share. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, research analysts predict that Alkermes plc will post 1.31 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ALKS. Royal Bank Of Canada decreased their price objective on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Wall Street Zen lowered Alkermes from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Zacks Research cut Alkermes from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Wells Fargo & Company lifted their price target on Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.07.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.